Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Current Leases (2019 - 2023)

Rein Therapeutics (RNTX) has disclosed Current Leases for 5 consecutive years, with $48000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Current Leases rose 45.45% to $48000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $48000.0, a 45.45% increase, with the full-year FY2023 number at $48000.0, up 45.45% from a year prior.
  • Current Leases was $48000.0 for Q4 2023 at Rein Therapeutics, up from $33000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $512000.0 in Q3 2020 to a low of $33000.0 in Q4 2022.
  • A 5-year average of $242875.0 and a median of $115500.0 in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: plummeted 81.84% in 2021, then soared 45.45% in 2023.
  • Rein Therapeutics' Current Leases stood at $446000.0 in 2019, then rose by 14.8% to $512000.0 in 2020, then tumbled by 81.84% to $93000.0 in 2021, then plummeted by 64.52% to $33000.0 in 2022, then skyrocketed by 45.45% to $48000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNTX's Current Leases are $48000.0 (Q4 2023), $33000.0 (Q4 2022), and $67000.0 (Q3 2022).